Abstract
A woman diagnosed of a renal cell carcinoma in 1989 had a metastatic kidney cancer localised in subcutaneous nodules, gut and lung in 2007. Sorafenib treatment was initiated a 400 mg orally twice a day. The patient developed generalised erythematous skin eruptions and two weeks later a widespread erythematous maculopapular eruption located exclusively on the legs and arms, along with an objective response. The most likely cause of the generalised erythematous skin eruptions was considered to be sorafenib because of the close temporal relationship between exposure to the drug and onset of symptoms. Furthermore, a relationship between sorafenib skin toxicity and treatment efficacy was observed. This therapeutic efficacy of EGFR inhibitors and cutaneous side effects should be better assessed in large cohorts or trials to determine whether the skin toxicity of patients can be linked to an objective antitumour response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bellmunt J, González-Larriba JL, Climent MA et al (2007) Sorafenib TARGET trial results in Spanish patients. Clin Transl Oncol 9:671–673
Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426–437
Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with treatment outcome? Eur J Cancer 42:548–556
Nexavar (sorafenib) tablets 200 mg [product information]. Bayer Pharmaceuticals, West Haven, CT. Available at: http://www.sciencedirect.com/science?_ob=RedirectURL&_method=externObjLink&_ locator=url&_plusSign=%2B&_targetURL=http%253A%252F%252Fwww.univgraph.com%252Fbayer%252Finserts%252FNexavarNAV_PI.pdf. Accessed 7 February 2008
Dasanu CA, Alexandrescu DT, Dutcher J (2007) Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 100:328–330
MacGregor JL, Silvers DN, Grossman ME, Sherman WH (2007) Sorafenib-induced erythema multiforme. J Am Acad Dermatol 56:527–528
Dilhuydy MS, Jouary T, Gomez A et al (2007) Severe erythema multiforme induced by two consecutive anti-angiogenic drugs. Eur J Cancer Suppl 5:30–31
Pfeiffer CM, Kazenoff S, Rothberg HD (1998) Toxic epidermal necrolysis from atorvastatin. JAMA 279:1613–1614
Frieze DA, McCune JS (2006) Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 40:241–250
Bajetta E, Procopio G, Verzoni E et al (2007) Renal cell cancer and sorafenib: skin toxicity and treatment outcome. Tumori 93:201–203
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galán Brotons, A., Borrás-Blasco, J., Rosique Robles, J.D. et al. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clin Transl Oncol 10, 844–846 (2008). https://doi.org/10.1007/s12094-008-0299-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0299-1